Gray, David Lawrence Firman,Zhang, Lei,Brodney, Michael Aaron,Green, Michael Eric,Subramanyam, Chakrapani
申请号：
AU2015249497
公开号：
AU2015249497A1
申请日:
2015.04.09
申请国别(地区):
AU
年份:
2016
代理人:
摘要：
The present invention provides, in part, compounds of Formula I: and pharmaceutically acceptable salts thereof； processes for the preparation of； intermediates used in the preparation of； and compositions containing such compounds or salts, and their uses for treating D1-mediated (or D1 -associated) disorders including, e.g., schizophrenia (e.g., its cognitive and negative symptoms), schizotypal personality disorder, cognitive impairment (e.g., cognitive impairment associated with schizophrenia, AD, PD, or pharmacotherapy therapy), ADHD, Parkinson's disease, anxiety, and depression.
